causal
Single-target cancer drugs fail due to mutation escape
Attacking a single cancer-driving pathway (e.g., inhibiting a tyrosine kinase locked 'on' by mutation) seemed promising but is too simple, because tumors become genomically unstable as they progress, acquire additional driver mutations downstream, and a tiny surviving fraction (1% or 0.1%) with another driver will inevitably grow out and kill the patient even if 99% of the tumor is destroyed.
causalpending
Speaker
James P. AllisonEvidence Quote
“You can cure 99%, kill 99% of the tumor cells doesn't make any difference because 1% or 0.1% will have another driver and they'll inevitably grow out and kill you.”
Created: 6/13/2026, 12:24:01 AM
Your notes
Loading notes...